Activation of fibrinolysis in the pericardial cavity after cardiopulmonary bypass

被引:30
作者
Khalil, PN
Ismail, M
Kalmar, P
von Knobelsdorff, G
Marx, G
机构
[1] Univ Hamburg, Hosp Eppendorf, Dept Thorac & Cardiovasc Surg, Hamburg, Germany
[2] Univ Hamburg, Hosp Eppendorf, Dept Anesthesiol, Hamburg, Germany
[3] Univ Hamburg, Hosp Eppendorf, Dept Blood Coagulat Disorder, Hamburg, Germany
关键词
fibrinolysis; haemostasis; kallikrein inhibitor; aprotinin; cardiopulmonary bypass;
D O I
10.1160/TH03-07-0455
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aprotinin is frequently administered systemically in patients undergoing cardiopulmonary bypass to preserve platelet function and ameliorate excessive activation of fibrinolysis. More recently, aprotinin topically applied in the pericardial cavity was also found to improve postoperative blood loss. However, platelet activation was not reduced locally during surgery. Hence, we investigated in the present prospective, in a randomized double-blind trial, the intra- and early postoperative state of systemic and local fibrinolytic activity, and whether topically administered aprotinin acts as an antifibrinolytic and therefore improves local hemostasis. Patients undergoing elective coronary artery bypass grafting were divided in two groups containing 22 patients each. Both, group I and II patients received high-dose aprotinin (6.0 x 10(6) kallikrein inhibitor units (KIU)) systemically. Before resuming extracorporeal circulation (ECC), either 1.0 X 10(6) KIU aprotinin (group I) or vehicle solution (group II) was applied into the pericardial cavity. Plasminogen, alpha(2)-antiplasmin, plasmin-alpha(2)-antiplasmin complex, plasminogen-activator-inhibitor type-I and D-dimers were measured in the pericardial cavity and systemic circulation immediately before resuming extracorporeal circulation (ECC), and at 1 h and 4 h postoperatively. The local fibrinolytic activity was found to significantly exceed that measured in the systemic circulation over time, whether of not they received aprotinin into the thoracic wound surface. Furthermore, evidence was provided that topically applied aprotinin reduces not only the local fibrinolytic activity but also the postoperative blood loss significantly by 33% which demonstrates the clinical relevance. The local activation of fibrinolysis seems to play an important role in blood loss after cardiopulmonary bypass. Therefore in fibrinolysis and blood coagulation the surgeon should not only consider what happens in the systemic circulation but also on a local level.
引用
收藏
页码:568 / 574
页数:7
相关论文
共 33 条
  • [1] Low-dose postoperative aprotinin reduces mediastinal drainage and blood product use in patients undergoing primary coronary artery bypass grafting who are taking aspirin: A prospective, randomized, double-blind, placebo-controlled trial
    Alvarez, JM
    Jackson, LR
    Chatwin, C
    Smolich, JJ
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2001, 122 (03) : 457 - 463
  • [2] BARTHELS M, 1993, GERINNUNGSANALYSEN I
  • [3] BIDSTRUP BP, 1989, J THORAC CARDIOV SUR, V97, P364
  • [4] BLAUHUT B, 1991, J THORAC CARDIOV SUR, V101, P958
  • [5] TOPICAL USE OF APROTININ IN CARDIAC-SURGERY
    CICEK, S
    TATAR, H
    DEMIRKILIC, U
    KURALAY, E
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1995, 110 (02) : 568 - 569
  • [6] Reexploration for hemorrhage following coronary artery bypass grafting - Incidence and risk factors
    Dacey, LJ
    Munoz, JJ
    Baribeau, YR
    Johnson, ER
    Lahey, SJ
    Leavitt, BJ
    Quinn, RD
    Nugent, WC
    Birkmeyer, JD
    O'Connor, GT
    [J]. ARCHIVES OF SURGERY, 1998, 133 (04) : 442 - 446
  • [7] Aprotinin in primary valve replacement end reconstruction: A multicenter, double-blind, placebo-controlled trial
    DAmbra, MN
    Akins, CW
    Blackstone, EH
    Bonney, SL
    Cohn, LH
    Cosgrove, DM
    Levy, JH
    Lynch, KE
    Maddi, R
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1996, 112 (04) : 1081 - 1089
  • [8] TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND FIBRIN MONOMERS SYNERGISTICALLY CAUSE PLATELET DYSFUNCTION DURING RETRANSFUSION OF SHED BLOOD AFTER CARDIOPULMONARY BYPASS
    DEHAAN, J
    SCHONBERGER, J
    HAAN, J
    VANOEVEREN, W
    EIJGELAAR, A
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1993, 106 (06) : 1017 - 1023
  • [9] METAANALYSIS OF PROPHYLACTIC DRUG-TREATMENT IN THE PREVENTION OF POSTOPERATIVE BLEEDING
    FREMES, SE
    WONG, BI
    LEE, E
    MAI, R
    CHRISTAKIS, GT
    MCLEAN, RF
    GOLDMAN, BS
    NAYLOR, CD
    [J]. ANNALS OF THORACIC SURGERY, 1994, 58 (06) : 1580 - 1588
  • [10] GRAM J, 1990, THROMB HAEMOSTASIS, V63, P241